Furthermore, the reported association between low decorin levels and more extensive peritoneal fibrosis in patients undergoing PD further strengthens the role of decorin as an anti-fibrotic agent and a potential therapeutic target in this population [18]. Here, DCN is linked to Peritoneal Fibrosis.